Spots Global Cancer Trial Database for pixantrone
Every month we try and update this database with for pixantrone cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma | NCT03458260 | Aggressive Non-... | Pixantrone Ifosfamide Etoposide Rituximab Transplant | 18 Years - | The Lymphoma Academic Research Organisation | |
| Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment | NCT01632436 | Metastatic Canc... | Pixantrone | 18 Years - | CTI BioPharma | |
| Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL | NCT00577161 | Non-Hodgkin's L... | fludarabine and... fludarabine, ri... | 18 Years - | CTI BioPharma | |
| Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment | NCT01632436 | Metastatic Canc... | Pixantrone | 18 Years - | CTI BioPharma | |
| Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer | NCT02800889 | Lymphoma Solid Tumor (Ex... | Pixantrone | 6 Months - 21 Years | CTI BioPharma | |
| BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | NCT00088530 | Lymphoma, Non-H... | pixantrone, cyc... Vinorelbine, Ox... | 18 Years - | CTI BioPharma | |
| Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma | NCT00060684 | Lymphoma, Low-G... Lymphoma, Small... Lymphoma, Mixed... Lymphoma, Small... | Pixantrone (BBR... fludarabine dexamethasone rituximab | 18 Years - | CTI BioPharma | |
| Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer | NCT02800889 | Lymphoma Solid Tumor (Ex... | Pixantrone | 6 Months - 21 Years | CTI BioPharma | |
| Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant | NCT01321541 | Diffuse Large B... de Novo DLBCL DLBCL Transform... Follicular Grad... | Pixantrone + Ri... Gemcitabine + R... | 18 Years - | CTI BioPharma | |
| Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL | NCT00577161 | Non-Hodgkin's L... | fludarabine and... fludarabine, ri... | 18 Years - | CTI BioPharma | |
| BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | NCT00088530 | Lymphoma, Non-H... | pixantrone, cyc... Vinorelbine, Ox... | 18 Years - | CTI BioPharma | |
| Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | NCT00060671 | Lymphoma, Folli... Lymphoma, Mixed... Lymphoma, Small... Lymphoma, Low-G... | rituximab Pixantrone (BBR... | 18 Years - | CTI BioPharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
